By Dani Kass ( September 22, 2016, 10:07 PM EDT) -- Mylan NV's planned introduction of a generic EpiPen is less likely an act of repentance after overcharging customers for a lifesaving drug and more a calculated move to secure loyalty ahead of competitors' entry to the market, as well as a means of cutting out middlemen who take a share of the profits, experts said Thursday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.